Head & Neck Cancers | Specialty

Study Shows No Survival Benefit of Cetuximab Over Cisplatin-Based Chemoradiation in Head and Neck Cancers

August 4th 2011

Patients with locally advanced head and neck cancer gained no survival benefit with the addition of cetuximab to chemoradiation.

Novel Therapeutics Target Gene Mutations, Tumor Suppressors

August 2nd 2011

Previously unknown genetic methylation patterns and new mutations for squamous cell carcinoma of the head and neck discovered.

Dr. Vogelzang Discusses Cabozantinib's Dose Size

June 29th 2011

Dr. NJ Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib's Dose Size

Dr. Vogelzang Describes Cabozantinib's Side Effects

June 21st 2011

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Hedgehog Pathway Inhibitor GDC-0449 Reduces Lesion Size in Patients With Basal Cell Carcinoma

June 20th 2011

Patients with basal cell carcinoma had an eightfold decrease in lesion area when treated with GDC-0449

Socioeconomic Status Bears Little Impact on Survival Rates

June 10th 2011

Primary cancers of the lung, esophagus, and pancreas-all of which have a poor prognosis-account for >35% of all cancer deaths in the United States annually

NCCN's 16th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care

May 24th 2011

Each year the National Comprehensive Cancer Network (NCCN) presents the latest updates to its Clinical Practice Guidelines in Oncology, as well as the latest cancer therapies by key opinion leaders.

Osteosarcoma Survivor Sings Message of Hope

May 9th 2011

Singer and songwriter Charlie Lustman has become an inspirational voice for the over 12 million cancer survivors living in the United States

FDA Approves Vandetanib for Metastatic Medullary Thyroid Cancer

April 7th 2011

The FDA has approved vandetanib for the treatment of unresectable, late-stage, metastatic medullary thyroid cancer

Dr. Langmuir Explains the Side Effects of Vandetanib

April 7th 2011

Childhood Radiation Exposure Risks Linger Beyond 50 Years

March 28th 2011

It has been more than half a century since radiation treatment was mistakenly deemed necessary to help infants with enlarged thymus glands avoid the risk of status lymphaticus and suffocation

Injection Laryngoplasty Is Effective for Laryngeal Dysfunction in Cancer Patients

March 25th 2011

New data suggest that office-based injection laryngoplasty (IL) appears to be a safe and effective treatment for laryngeal dysfunction in cancer patients.

Prereferral Treatment of Head and Neck Cancer Patients Disregards Guidelines

March 16th 2011

New findings indicate that prereferral care does not conform to clinical practice guidelines in nearly half of patients with head and neck cancer who are referred to a tertiary care center with persistent or recurrent disease, new findings indicate.

Net Guides: Head and Neck Cancers

March 15th 2011

Useful Online Resources and Clinical Trials for Head and Neck Cancers

Vandetanib Advantages in Medullary Thyroid Cancer

March 15th 2011

Dr. Langmuir on Vandetanib in Medullary Thyroid Cancer

March 15th 2011

Dr. Langmuir Discusses Vandetanib Clinical Trials

March 15th 2011

eter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses the vandetanib clinical trials.

Dental Care Steps to Prevent and Treat Osteonecrosis of the Jaw

March 14th 2011

Everyone can benefit from good oral hygiene, but people with cancer need to pay particular attention to their dental health

The Emperor of All Maladies: Documenting Cancer's Long Reign

March 12th 2011

The Emperor of All Maladies bills itself as a "biography of cancer," and while author Siddhartha Mukherjee cannot tell us precisely when cancer opened its eyes in this world...

FDA Approves Zactima

March 9th 2011

An FDA advisory panel voted 10 to 0 in favor of approving Zactima (vandetanib) for patients with medullary thyroid cancer who have symptomatic, progressive disease.